Targets › PDPN
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Sep 2027.
Mediates effects on cell migration and adhesion through its different partners. During development plays a role in blood and lymphatic vessels separation by binding CLEC1B, triggering CLEC1B activation in platelets and leading to platelet activation and/or aggregation. (UniProt, Q86YL7)
Open in Phaseline: the race on PDPN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Envolizumab Anti-podoplanin monoclonal antibody | PDPN | Phase 2 | Head and Neck Cancer | Sep 2027 |
Head and Neck Cancer (1)
antibody (1)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.